[vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].

Targeted therapy for V600 BRAF mutant solid tumors already exists but resistance to the treatment is still a serious problem to be solved. Moreover, there are currently no approved targeted therapeutic options against non-V600 BRAF mutant tumors. Here we studied targeted therapy resistance mechanisms of V600 BRAF mutant melanoma and also explored potential alternative solutions for their treatment. In V600 BRAF mutant melanoma cells that did not...